RVNC News and Press, Revance Therapeutics Inc. From 08/28/19

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will participate in the Wells Fargo 14th Annual Healthcare Conference, in Boston, MA. President and ...

Revance Therapeutics (NASDAQ: RVNC ): Q2 GAAP EPS of -$0.86 beats by $0.04 . More news on: Revance Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...

- Conference call and webcast today at 4:30 p.m. ET - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today reported financial results for the quarter ended June 30, 2019 and pro...

Conference Call Scheduled for Monday, August 5, 2019 at 4:30 p.m. ET Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company pioneering new innovations in neuromodulators for aesthetic and therapeutic indications, today announced that the company will release second quarter ...

Revance ( RVNC ) is a clinical stage biotech company that is looking to enter into the botulinum toxin market. Its lead formulation appears to be differentiated from current options, which may lend it an edge when it enters the market. However, over the course of the past year it seems that a ...

- Nolet will serve as Chair of the Audit Committee - ​Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the appointment of Chr...

Prior to the announced merger with Allergan ( AGN ) AbbVie ( ABBV ) had already been a complicated stock to understand. On the one hand, you had a fantastic dividend growth stock with a 5% and higher yield, double-digit earnings and dividend growth and the world's best-selling drug ever as i...

Agilent (NYSE: A ) initiated with Overweight rating and $83 (18% upside) price target at Piper Jaffray. More news on: Agilent Technologies, Inc., Danaher Corporation, Teleflex Incorporated, Healthcare stocks news, Stocks on the move, , Read more ...

- Beraud will also chair newly-formed Brand Strategy Committee - Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing a new category of high-performance neuromodulators for use in treating aesthetic and therapeutic conditions, today announced the appointment o...

Revance Therapeutics, Inc. (Nasdaq: RVNC), a biotechnology company developing next-generation neuromodulators for use in treating aesthetic and therapeutic conditions, today announced that the company will participate in the Goldman Sachs 40th Annual Global Healthcare Conference in Rancho Pa...